Impact Selected to Present at 2019 BioCentury NewsMakers Conference
Impact Therapeutics Inc. (“Impact”) was selected to present at BioCentury NewsMakers Conference on September 6th, 2019 in New York City. Dr. Jun Bao, President and CEO of Impact, presented company overview and progress of R&D pipeline to investment firms. NewsMakers Conference is recognized as the industry's key venue for companies to take their story to investment community each fall. Two weeks prior to the conference, BioCentury published a feature article on Impact in emerging company section, highlighting Impact as a global player in the area of synthetic lethality. Click here for details.
Impact is a privately held clinical-stage biopharmaceutical company incorporated in Nanjing, China, dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. Impact has made tremendous progress in several novel drug R&D projects, including PARP inhibitor, Wee1 inhibitor, other novel DDR agents and hedgehog pathway inhibitor. The lead program PARP inhibitor IMP4297 is ready for Phase 3 study in China. Impact is currently seeking investors to lead series D fund raising to support further development of R&D pipeline.